Wedbush analyst Yun Zhong has reiterated their bullish stance on IRD stock, giving a Buy rating on November 6.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Yun Zhong has given his Buy rating due to a combination of factors including the positive feedback from the FDA regarding Opus Genetics’ RPGx-LCA5 program, which is seen as beneficial for the RPGx-BEST1 program as well. The ongoing patient enrollment in the adaptive, open-label, dose-exploring study is progressing, with initial data expected in the first quarter of 2026. Additionally, the company’s financial position is strong, with a cash runway supported into the second half of 2027, thanks to recent fundraising efforts and non-dilutive funding.
Moreover, the completion of enrollment in the pivotal Phase 3 LYNX-3 study and the anticipated data release in the first half of 2026 are seen as significant milestones. The adaptive design of the OPGx-BEST1 study, which includes thorough safety and efficacy evaluations, further supports the potential for positive outcomes. These factors, combined with the company’s strategic advancements and regulatory support, underpin Yun Zhong’s positive outlook and Buy rating for Opus Genetics.